NASDAQ: KROS
Keros Therapeutics Inc Stock Ownership - Who owns Keros Therapeutics?

Insider buying vs selling

Have Keros Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Orbimed Advisors LLCDirector2025-11-2174,465$17.75
$1.32MSell
Carl L. GordonDirector2025-11-21140,057$17.75
$2.49MSell
Carl L. GordonDirector2025-11-2174,465$17.75
$1.32MSell
Julius KnowlesDirector2025-11-21191,527$17.75
$3.40MSell
Julius KnowlesDirector2025-11-21130,494$17.75
$2.32MSell
Orbimed Advisors LLCDirector2025-11-21140,057$17.75
$2.49MSell
Pontifax Management 4 GP 2015 Ltd10% Owner2025-10-151,226,412$17.75
$21.77MSell
Pontifax Management 4 GP 2015 Ltd10% Owner2025-10-15155,262$17.75
$2.76MSell
Adar1 Capital Management LLC10% Owner2025-10-154,391,237$17.75
$77.94MSell
Adar1 Capital Management LLC10% Owner2025-10-15254,669$17.75
$4.52MSell

1 of 3

KROS insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when KROS insiders and whales buy or sell their stock.

KROS Shareholders

What type of owners hold Keros Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Adar1 Capital Management LLC17.69%5,389,264$103.47MInstitution
Vanguard Group Inc8.92%2,718,777$52.20MInstitution
Blackrock Inc8.92%2,717,153$52.17MInstitution
Madison Avenue Partners LP8.89%2,708,218$52.00MInstitution
Western Standard LLC7.19%2,189,882$42.05MInstitution
Alon Lazarus6.68%2,036,140$39.09MInsider
Arkin Bio Ventures Limited Partnership6.61%2,013,102$38.65MInsider
Tang Capital Management LLC4.66%1,418,984$27.24MInstitution
D E Shaw Co Inc4.37%1,331,425$25.56MInstitution
Goldman Sachs Group Inc4.35%1,325,483$25.45MInstitution

1 of 3

KROS vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
KROS79.60%20.40%Net SellingNet Selling
FULC65.04%34.96%Net SellingNet Selling
DSGN45.88%54.12%Net Selling
NBY0.10%99.90%Net Buying
DRTS2.15%0.00%

Keros Therapeutics Stock Ownership FAQ

Who owns Keros Therapeutics?

Keros Therapeutics (NASDAQ: KROS) is owned by 115.80% institutional shareholders, 29.68% Keros Therapeutics insiders, and 0.00% retail investors. Alon Lazarus is the largest individual Keros Therapeutics shareholder, owning 2.04M shares representing 6.68% of the company. Alon Lazarus's Keros Therapeutics shares are currently valued at $39.09M.

If you're new to stock investing, here's how to buy Keros Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.